Kamada screens as attractively valued with a favorable modeled asymmetry of 47.3% upside versus 6.9% downside, but the analysis flags two consecutive earnings misses, weak growth, and a leverage penalty for its 4.5x debt-to-equity ratio, prompting a note to consider reducing the position despite a strong underlying Piotroski F-Score.
Thesis pillars
- Asymmetric Risk Reward→Stable
- Consecutive Earnings Misses↑Improving
- Leverage Penalty Risk↑Improving
- +2 more pillars — see the Why tab for full reasoning
Kamada Ltd. (KMDA) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Wait — supporting gate not met yet. Price is at or below entry $7.10 but weak momentum still blocks BUY_NOW. Key risks: Weak growth; Negative momentum.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post... Read more
Wait — supporting gate not met yet. Price is at or below entry $7.10 but weak momentum still blocks BUY_NOW. Key risks: Weak growth; Negative momentum. Chart setup: RSI 53 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Score 5.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: aggressive.
Recent developments
updated 2026-08-12Recent Developments — Kamada Ltd.
Latest news
- NEWS Kamada Sets August 12 Release for Q2 and First-Half 2026 Results - TipRanks — TipRanks neutral
- NEWS Kamada Ltd Director Uri Botzer Granted 30,000 Stock Options Under 2011 Plan - Kalkine Media — Kalkine Media neutral
- NEWS Options Exercise Activity Initiated By Leon Recanati At Kamada Worth $0 - Benzinga — Benzinga neutral
- NEWS Options Exercise Update At Kamada: Lilach Payorski Engages, Resulting In $0 - Benzinga — Benzinga neutral
- NEWS Options Exercise Activity Initiated By Leon Recanati At Kamada Worth $0 - benzinga.com — benzinga.com neutral
Generated 2026-08-14T14:47:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $7.10 but weak momentum still blocks BUY_NOW. Key risks: Weak growth; Negative momentum. Chart setup: RSI 53 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Target $11.05 (+55.9%), stop $6.77 (−4.7%), A.R:R 11.2:1. Score 5.7/10, moderate confidence.
Take-profit target: $11.05 (+55.9% upside). Target $11.05 (+55.9%), stop $6.77 (−4.7%), A.R:R 11.2:1. Stop-loss: $6.77.
Weak growth; Negative momentum; Value-trap signals (3/5): Margin compression (op margin -137.4%), Material insider selling (27 sells, 0.30% of cap), Negative free cash flow.
Kamada Ltd. trades at a P/E of 20.4 (forward 11.6). TrendMatrix value score: 8.3/10. Verdict: Buy (Wait for Entry).
9 analysts cover KMDA with a consensus score of 4.2/5. Average price target: $13.
What does Kamada Ltd. do?Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as...
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.